<DOC>
	<DOCNO>NCT00827840</DOCNO>
	<brief_summary>Primary objective : To examine whether switch paliperidone ER risperidone improve cognitive function stabilize patient schizophrenia . Secondary objective : To compare general clinical outcome ( efficacy safety ) switch paliperidone ER risperidone</brief_summary>
	<brief_title>Paliperidone Extended-Release ( ER ) Versus Risperidone Neurocognitive Function Patients With Schizophrenia</brief_title>
	<detailed_description>This 12-week , randomize , parallel-group , open label , flexible-dose study . The patient randomize risperidone-continuation group continue receive risperidone , paliperidone-switch group switch risperidone paliperidone . In paliperidone-switch group , risperidone taper first 4 week study , paliperidone titrate simultaneously . The dos drug adjust accord clinical judgment research psychiatrist , within 6 mg/day risperidone 12 mg/day paliperidone .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Patients diagnose schizophrenia DSMIVTR criterion inpatient Patients symptomatically stable , judged treat psychiatrist , receive stable dose risperidone minimum 2 week enrollment . Patients ability complete various questionnaire . Patients and/or legal guardians/representatives sufficiently understand objective study sign inform consent form Active psychotic symptom , include severe behavioral disturbance Relevant history current presence significant unstable medical disease A woman pregnant , breastfeed plan become pregnant study period Patients history serious allergy multiple adverse drug reaction Patients history take paliperidone ER within 60 day Patients history take clozapine within 60 day Patients require treatment medication influence CNS , except permit concomitant drug advance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>